Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States

被引:275
作者
Welzel, Tania M. [1 ]
McGlynn, Katherine A. [1 ]
Hsing, Ann W. [1 ]
O'Brien, Thomas R. [1 ]
Pfeiffer, Ruth M. [1 ]
机构
[1] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
关键词
D O I
10.1093/jnci/djj234
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Cholangiocarcinomas are topographically categorized as intrahepatic or extrahepatic by the International Classification of Diseases for Oncology (ICD-O). Although hilar cholangiocarcinomas (Klatskin tumors) are extrahepatic cholangiocarcinomas, the second edition of the ICD-O (ICD-O-2) assigned them a histology code 8162/3, Klatskin, which was cross-referenced to intrahepatic cholangiocarcinoma. Recent studies in the United States that included this code (8162/3, Klatskin) with intrahepatic cholangiocarcinoma reported an increasing incidence of intrahepatic cholangiocarcinoma and a decreasing incidence of extrahepatic cholangiocarcinoma. To investigate the impact of this misclassification on site-specific cholangiocarcinorna incidence rates, we calculated annual percent changes (APCs) with data from the Surveillance, Epidemiology, and End Results (SEER) program using a Poisson regression model that was age-adjusted to the year 2000 U.S. population. All statistical tests were two-sided. During 1992-2000, when SEER used ICD-O-2, 1710 intrahepatic cholangiocarcinomas, 1371 extrahepatic cholangiocarcinomas, and 269 hilar cholangiocarcinomas identified by code 8162/3, Klatskin were diagnosed. Ninety-one percent (246 of 269) of the hilar cholangiocarcinomas were incorrectly coded as intrahepatic cholangiocarcinomas, resulting in an overestimation of intrahepatic cholangiocarcinorna incidence by 13% and underestimation of extrahepatic cholangiocarcinomas incidence by 15%. However, even after the exclusion of tumors that were coded to the histology code 8162/3, Klatskin, age-adjusted annual intrahepatic cholangiocarcinoma incidence increased during this period (APC = 4%, 95% confidence interval = 2% to 6%, P <.001).
引用
收藏
页码:873 / 875
页数:3
相关论文
共 18 条
[1]
Medical progress - Biliary tract cancers [J].
de Groen, PC ;
Gores, GJ ;
LaRusso, NF ;
Gunderson, LL ;
Nagorney, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (18) :1368-1378
[2]
Fritz AG, 2013, International classification of diseases for oncology, V3
[3]
Hamilton S.R., 2000, WHO CLASSIFICATION T
[4]
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma - Implications for adjuvant therapeutic strategies [J].
Jarnagin, WR ;
Ruo, L ;
Little, SA ;
Klimstra, D ;
D'Angelica, M ;
DeMatteo, RP ;
Wagman, R ;
Blumgart, LH ;
Fong, YM .
CANCER, 2003, 98 (08) :1689-1700
[5]
Khan SA, 2002, GUT, V51, P1
[7]
Cholangiocarcinoma [J].
Lazaridis, KN ;
Gores, GJ .
GASTROENTEROLOGY, 2005, 128 (06) :1655-1667
[8]
Logrono R, 2000, ARCH PATHOL LAB MED, V124, P387
[9]
Cholangiocarcinoma - A spectrum of intrahepatic, perihilar, and distal tumors [J].
Nakeeb, A ;
Pitt, HA ;
Sohn, TA ;
Coleman, J ;
Abrams, RA ;
Piantadosi, S ;
Hruban, RH ;
Lillemoe, KD ;
Yeo, CJ ;
Cameron, JL .
ANNALS OF SURGERY, 1996, 224 (04) :463-473
[10]
*NAT CANC I, 2001, SURV EP END RES SEER